Adaptive Biotechnologies Corporation reported earnings results for the fourth quarter and full year ended December 31, 2023. For the fourth quarter, the company reported sales was USD 45.78 million compared to USD 55.2 million a year ago. Net loss was USD 69.44 million compared to USD 40.13 million a year ago. Basic loss per share from continuing operations was USD 0.48 compared to USD 0.28 a year ago.
For the full year, sales was USD 170.28 million compared to USD 185.31 million a year ago. Net loss was USD 225.25 million compared to USD 200.19 million a year ago. Basic loss per share from continuing operations was USD 1.56 compared to USD 1.4 a year ago.